{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:28:30Z","timestamp":1787495310486,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tjog.2024.12.027","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:28:13Z","timestamp":1747074493000},"page":"524-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Complete remission of endometrial cancer stage IVC treated with multimodality treatment including immunotherapy and maintenance PARP inhibitor \u2013 A case report"],"prefix":"10.1016","volume":"64","author":[{"given":"You-Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Yin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2024.12.027_bib1","series-title":"Cancer registry annual report","year":"2021"},{"key":"10.1016\/j.tjog.2024.12.027_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.tjog.2024.12.027_bib3","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.12.027_bib4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.12.027_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.tjog.2024.12.027_bib6","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1159\/000510000","article-title":"Complete clinical response in stage IVB endometrioid endometrial carcinoma after first-line pembrolizumab therapy: report of a case with isolated loss of PMS2 protein","volume":"13","author":"Carvalho","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2022.107125","article-title":"Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: a case report","volume":"94","author":"Taguchi","year":"2022","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.tjog.2024.12.027_bib10","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.12.027_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/IGC.0000000000000352","article-title":"Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria","volume":"25","author":"Volgger","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.12.027_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib13","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.12.027_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.12.027_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5468\/ogs.21219","article-title":"Management of inoperable endometrial cancer","volume":"65","author":"Pitakkarnkul","year":"2022","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.tjog.2024.12.027_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/IGC.0000000000001296","article-title":"A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN study group","volume":"28","author":"Bricou","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.12.027_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2022.06.011","article-title":"Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis","volume":"166","author":"Heffernan","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib18","series-title":"The NCCN clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) uterine neoplasms","volume":"vol. 1","year":"2024"},{"key":"10.1016\/j.tjog.2024.12.027_bib19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.tjog.2021.07.030","article-title":"Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports","volume":"60","author":"Tung","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.12.027_bib20","article-title":"Clinical outcomes of intensity modulated proton therapy reirradiation for gynecologic malignancies","volume":"8","author":"Pollock","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.12.027_bib22","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.12.027_bib23","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2024.12.027_bib24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.tjog.2024.12.027_bib25","doi-asserted-by":"crossref","first-page":"S1283","DOI":"10.1016\/j.annonc.2023.10.036","article-title":"Olaparib vs placebo as maintenance therapy after platinumbased chemotherapy in advanced\/metastatic endometrial cancer patients: the GINECO randomized phase IIb UTOLA trial","volume":"34","author":"Lobbedez","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:28:16Z","timestamp":1747074496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1028455925000877"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2024.12.027","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete remission of endometrial cancer stage IVC treated with multimodality treatment including immunotherapy and maintenance PARP inhibitor \u2013 A case report","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2024.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}